Phs 398 (rev. 9/04), biographical sketch format page

Professor, Univ. of Maryland, Baltimore Chief Scientific Officer, AllTranz Inc. EDUCATION/TRAINING (Begin with baccalaureate or other initial professional education, such as nursing, and include postdoctoral training.) University of Colorado, Boulder/Denver, CO The University of Michigan, Ann Arbor, MI University of California, San Francisco, CA Personal Statement
I have been studying transdermal drug delivery since 1989, and believe that I can help establish significant translational research projects in various treatment areas. I have already started a translational research project with NIDA funding from proof-of-concept to a Phase I clinical trial for marijuana dependence and abuse treatment. I have also completed a proof-of-concept human study with a microneedle drug delivery system and naltrexone, a treatment for alcoholics and heroin addicts (R01DA13425). I have been able to coordinate and move forward six different drug development projects for alcohol and drug abuse treatment, because of my unique combined position as a Professor and private industry Chief Scientific Officer. This public-private partnership makes it possible to accelerate drug development and commercialization of promising drug and vaccine candidates. I am intimately involved with the drug development process from drug synthesis to clinical trials on a daily basis. I believe that my training and experience in this area of dermal drug delivery and development makes me an ideal investigator for this project. Positions and Honors.
1996-01 Assistant Professor of Pharmaceutics, Albany College of Pharmacy, Albany, NY
2001-04 Assistant Professor, University of Kentucky College of Pharmacy, Lexington, KY
2004- Chief Scientific Officer and Founder of AllTranz, Inc, a specialty pharmaceutical company
2005-11 Associate Professor, University of Kentucky College of Pharmacy, Lexington, KY
2011 Professor, University of Kentucky College of Pharmacy, Lexington, KY
2011 Professor, University of Maryland, Baltimore, School of Pharmacy, Baltimore, MD
2010 Kentucky Entrepreneur Hall of Fame
2010 Springboard Portfolio Company, All Things Life Sciences 2010
2011 AAPS Fellow
Journal Editorial Advisory Boards: Pharmaceutical Research, Journal of Pharmaceutical Sciences,
Substance Abuse: Research and Treatment, Recent Patents on Drug Delivery and Formulation,
Therapeutic Delivery, Transdermal, Clinical Pharmacology: Current Research, Medicinal Chemistry:
Current Research
Stinchcomb AL, Swaan PW. Transdermal Delivery of Opioid Antagonist Prodrugs. U.S. Patent 6,569,449.
Issued May 27, 2003. Filed November 13, 2000. Hinds BJ, Stinchcomb AL. Delivery System for a Composition. US Patent 7,229,556. Issued June 12, 2007. Stinchcomb AL, Golinski MJ, Hammell DC, Howard JL. Transdermally deliverable opioid prodrugs, abuse- resistant compositions and methods of using opioid prodrugs. US Patent 7,511,054. Issued March 31, 2009. Filed September 24, 2007. Crooks, Peter A.; Hamad, Mohamed Omer; Stinchcomb, Audra Lynn. Novel oral bioavailable prodrugs. US Patent 7,759,358. Issued July 20, 2010. Selected peer-reviewed publications. (Selected from 58 peer-reviewed publications)
1. Flux across microneedle-treated skin is increased by increasing charge of naltrexone and naltrexol in vitro.
Banks SL, Pinninti RR, Gill HS, Crooks PA, Prausnitz MR, Stinchcomb AL. Pharmaceutical Research. 25(7):1677-85 (2008). PMID: 18449628. PMCID: 141780. 2. Microneedles permit transdermal delivery of a skin-impermeable medication to humans. Wermeling D,
Banks SL, Gill H, Gupta J, Prausnitz M, Stinchcomb AL. Proc. Natl. Acad. Sci. 105(6):2058-2063 (2008). PMID: 18250310 3. Transdermal delivery of naltrexol and skin permeability lifetime after microneedle treatment in hairless
guinea pigs in vivo. Banks SL, Pinninti RR, Gill HS, Paudel KS, Crooks PA, Brogden NK, Prausnitz MR, Stinchcomb AL. JPharmSci. 99(7):3072-80 (2010). PMID: 20166200. PMCID: 2862091. 4. Vehicle composition influence on the microneedle-enhanced transdermal flux of naltrexone
hydrochloride. Milewski, M, Stinchcomb, AL. PharmRes. 28(1):124-34 (2011). PMID: 20577787 5. Diclofenac enables prolonged delivery of naltrexone through microneedle treated skin. Banks SL,
Paudel KS, Brogden NK, Loftin CD, Stinchcomb AL. PharmRes. 28(5):1211-9(2011). PMID: 21301935. 6. A Duplex “Gemini” Prodrug of Naltrexone for Transdermal Delivery. D.C. Hammell, M. Hamad, H.K.
Vaddi, P.A. Crooks, A.L. Stinchcomb. Journal of Controlled Release. 97:283-290 (2004). PMID: 15196755 7. In Vitro/In Vivo Correlation of Transdermal Naltrexone Prodrugs in Hairless Guinea Pigs. Valiveti S,
Paudel KS, Hammell DC, Hamad MO, Chen J, Crooks PA, Stinchcomb AL. Pharmaceutical Research. 22(6):981-9 (2005). PMID: 15948042 8. In Vivo Evaluation of 3-O-Alkyl Ester Transdermal Prodrugs of Naltrexone in Hairless Guinea Pigs. S.
Valiveti, D.C. Hammell, K.S. Paudel, M.O. Hamad, P.A. Crooks, A.L. Stinchcomb. Journal of Controlled Release. 102(2):509-520 (2005). PMID: 15653167 9. Enhancement of transdermal delivery of 6-β-naltrexol via a codrug linked to hydroxybupropion. Kiptoo
PK, Hamad MO, Crooks PA, Stinchcomb AL. Journal of Controlled Release. 113(2):137-145 (2006). PMID: 16750868 10. Prodrugs and codrugs as strategies for improving percutaneous absorption. Strasinger CL, Scheff NN,
Stinchcomb AL. Expert Review of Dermatology. 3(2):221-233 (2008). 11. Carbon Nanotube Membranes for use in the Transdermal Treatment of Nicotine Addiction and Opioid
Withdrawal Symptoms. Strasinger CL, Scheff NN, Wu J, Hinds BJ, Stinchcomb AL. Substance Abuse: Research and Treatment. 3 (2009). PMCID: 150672. 12. Development of Opioid Transdermal Delivery Systems. Paudel KS, Banks SL, Kiptoo PK, Hammell DC,
Pinninti RR, Strasinger CL, Stinchcomb AL. In: "Opioid Receptors and Antagonists: From Bench to Clinic" (1st edition), R. Dean, E. Bilsky, S. Negus (eds), Humana Press. (2009). 13. Programmable transdermal drug delivery of nicotine using carbon nanotube membranes. Wu J,
Paudel KS, Strasinger C, Hammell DC, Stinchcomb AL, Hinds BJ. Proc. Natl. Acad. Sci. 107(26):11698-11702 (2010). 14. The role of entrepreneurial activities in academic pharmaceutical science research. Stinchcomb, AL.
JPharmSci. 99(6):2532-2537 (2010). 15. In vitro permeation of a pegylated naltrexone prodrug across microneedle-treated skin. Milewski M,
Yerramreddy TR, Ghosh P, Crooks P, Stinchcomb AL. JControlledRelease. 146(1):37-44 (2010). 16. Current aspects of formulation efforts and pore lifetime related to microneedle treatment of skin.
Milewski, M, Brogden, N, Stinchcomb, AL. Expert Opinion on Drug Delivery. 7(5):617-29 (2010). PMID: 20205604. PMCID: 2858255.


Microsoft powerpoint - psy3071 conflits.ppt

1. Conflit: définition et caractéristiques 2. Trois modalités de gestion de conflits – Retrait et demandes / retrait – Confrontation – Mode adéquat de résolution de conflits 3. Attributions causale et conflits interpersonnels 4. L’effet de la « négativité » des émotions sur la vie de couple Les conflits interpersonnels: définition Le conflit est une confr


Anlage zur Akkreditierungsurkunde DGA-ML-6096.00 (06.10.2009)DGA Deutsche Gesellschaft für Akkreditierung mbH Anlage zur Akkreditierungsurkunde DGA-ML-6096.00 (06.10.2009) Die Akkreditierung ist gültig bis: 05.10.2014 MVZ Diamedis GmbH Diagnostische Medizin Sennestadt Dunlopstraße 50 Husener Straße 46a 33689 Bielefeld 33098 Paderborn Untersuchungen im Bereich Medizini

Copyright © 2018 Medical Abstracts